NIVOLUMAB for Sarcoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 124 adverse event reports in the FDA FAERS database where NIVOLUMAB was used for Sarcoma.
Most Reported Side Effects for NIVOLUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 11,216 | 12.8% | 11,211 | 780 |
| Malignant neoplasm progression | 9,363 | 10.7% | 5,146 | 4,330 |
| Off label use | 5,208 | 5.9% | 1,240 | 1,725 |
| Diarrhoea | 4,692 | 5.4% | 623 | 2,506 |
| Fatigue | 3,709 | 4.2% | 409 | 1,425 |
| Pyrexia | 3,454 | 3.9% | 532 | 2,501 |
| Intentional product use issue | 3,297 | 3.8% | 1,461 | 827 |
| Rash | 2,816 | 3.2% | 297 | 1,131 |
| Nausea | 2,805 | 3.2% | 378 | 1,495 |
| Decreased appetite | 2,619 | 3.0% | 452 | 1,429 |
| Dyspnoea | 2,527 | 2.9% | 596 | 1,575 |
| Pneumonia | 2,281 | 2.6% | 792 | 1,676 |
| Colitis | 2,123 | 2.4% | 333 | 1,306 |
| Pneumonitis | 2,076 | 2.4% | 564 | 1,130 |
| Hypothyroidism | 1,939 | 2.2% | 267 | 946 |
Other Indications for NIVOLUMAB
Product used for unknown indication (12,733)
Malignant melanoma (10,599)
Non-small cell lung cancer (9,987)
Renal cell carcinoma (6,514)
Metastatic malignant melanoma (4,628)
Lung neoplasm malignant (4,197)
Metastatic renal cell carcinoma (3,857)
Gastric cancer (3,856)
Non-small cell lung cancer recurrent (2,703)
Renal cancer (1,756)
Other Drugs Used for Sarcoma
DOXORUBICIN (409)
PAZOPANIB (296)
IFOSFAMIDE (280)
EPIRUBICIN (132)
VINCRISTINE (105)
CYCLOPHOSPHAMIDE (79)
ETOPOSIDE (75)
TRABECTEDIN (75)
TRONOXAL INYECTABLE (74)
IPILIMUMAB (58)